Hims & Hers Stock Climbs on Peptide Policy Shift

Hims & Hers (HIMS) stock rose after the company said in a press release on April 15, 2026, that it is exploring peptide therapies and welcomed FDA steps to clarify the regulatory status of several peptides. This move could allow the company to offer compounded peptide products if regulators approve.

FDA Review Timeline and Regulatory Context

The Food and Drug Administration is seeking to remove 12 peptides from Category 2, a high-risk designation that currently bars compounding of these substances. This effort aims to shift demand from illicit sources to regulated compounding pharmacies and reshape peptide regulation. Officials described the step as an initial procedural action rather than formal approval. The agency also clarified its policy on GLP-1 compounding on April 1, 2026.

The FDA’s Pharmacy Compounding Advisory Committee will meet July 23–24, 2026, to review evidence on whether to add these peptides to the 503A Bulks List, which would permit compounding. The agency’s evaluation is expected to continue through February 2027. HHS Secretary Robert F. Kennedy Jr. said the panel will assess scientific merits and safety to move access into regulated channels.

Hims & Hers’ Strategic Positioning

Hims & Hers said it is exploring peptide therapies aligned with FDA guidance for consumer safety and clinical excellence. The company expanded its manufacturing footprint by acquiring a California facility in 2025 to broaden peptide offerings, including weight-loss and muscle-recovery formulations. Management has presented this site as part of a buildout to support peptide production if compounding rules change.

The company signaled peptide interest to investors during its February 2026 earnings call before the April statement. It plans to leverage compounding capabilities developed amid the GLP-1 treatment market, focusing on in-house supply rather than outsourcing production.

An analyst note raised the price target to $25 from $21 and maintained a Neutral rating, citing potential peptide revenue upside. The note applied a higher valuation multiple, about 25.5 times versus the prior 21.5 times, while leaving near-term earnings forecasts unchanged. This adjustment reflects optionality rather than immediate profit impact.

Hims & Hers serves more than 2 million subscribers and had a market capitalization of about $5.5 billion as of April 16, 2026. Insiders sold roughly $3.4 million of stock in the past three months and reported no insider buys. The company trades at a price-to-earnings ratio in the mid-40s, highlighting a contrast between market enthusiasm for regulatory progress and near-term fundamentals.

Dr. Pat Carroll, Hims & Hers’s chief medical officer, said the company’s medical team “believes certain peptide therapies hold meaningful potential in helping Americans live healthier lives.”

Regulators’ decisions will determine whether that potential can be realized commercially. A permissive advisory recommendation and subsequent agency action could open a regulated compounding channel, allowing Hims & Hers to translate manufacturing capacity and subscriber scale into new revenue. A more restrictive outcome would close that route and leave the opportunity unrealized.